DMDina Mansour

Dina Mansour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dina Mansour has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    British Society of Gastroenterology position statement on the American Association for the Study of Liver Disease practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis

    by Philip D J Dunne, Dhiraj Tripathi, David Patch, Vishal C Patel, James B Maurice, Mark McPhail, Lynsey Corless, Dianne Backhouse, Ian A Rowe, Ewan Forrest, et al.

    The British Society of Gastroenterology (BSG) recognises that the current UK guideline on the management of variceal bleeding in cirrhotic patients (2015)1 requires updating. Recent updates to similar international guidance including the American Association for the Study of Liver Disease (AASLD),2 European Society of Gastrointestinal Endoscopy (ESGE)3 and Baveno VII,4 as well as updated NICE cirrhosis guidelines5 are acknowledged by the Clinical Guidelines Development (CGD) group. However, the CGD are also mindful of the large-scale, multicentre UK studies recently completed or currently in progress addressing both primary and secondary prophylaxis of variceal bleeding, with results expected to significantly influence UK best practice. Therefore, the CGD has opted to produce a position statement on the latest international guidance, while these data are pending. This decision is supported by the BSG Clinical Services (CS) committee. Furthermore, prioritising the identification of clinically significant portal hypertension (CSPH), rather than the management of varices alone, was felt to be an important shift in practice. On review, the CGD agreed that the AASLD guidance was most consistent with UK clinical practice. Therefore, the BSG endorses the interim use of the AASLD guidance in the UK, with some important caveats. The individual AASLD guidance statements are reproduced below, with necessary caveats added where applicable. These caveats primarily pertain to the recommendations for diagnosis of CSPH including the role of non-invasive tests (NITs), defining indications for non-selective beta-blockers (NSBB) and use of pre-emptive transjugular intrahepatic portosystemic shunt (pTIPSS) following acute oesophageal variceal bleeding (OVB).

  • Open Access

    Management of acute decompensated cirrhosis

    by Dina Mansour


  • Development and feasibility of a patient-reported experience survey for outpatients with liver disease

    by Oliver D Tavabie, Amy Johnson, Felicity Williams, Vanessa Hebditch, Safa Al-Shamma, Dina Mansour

    Objective To design a patient-reported experience survey (PRES) for outpatients with liver disease and to understand the feasibility of delivering the survey. Design/methods A PRES was codeveloped by healthcare professionals (HCPs) and patient representatives and included questions covering: patient expectations, understanding and involvement with care, stigma and communication. A feasibility study was undertaken at Leeds Teaching Hospitals NHS Trust (LTHT), University Hospitals Dorset NHS Foundation Trust (UHD) and Gateshead Health NHS Foundation Trust (GHT). Response rate was assessed using a margin of error calculation with a threshold set Results A total of 122 responses from 1182 patients (10.3%) were received, achieving a projected margin of error of 8.4% for the total sample. However, no individual site achieved a projected margin of error Conclusion We have developed a PRES specifically for outpatients with liver disease. While it is feasible to deliver the survey to understand national experience, there are challenges in achieving an adequate response rate to allow for comparison of centres. Further work is required to improve representation and response rate of surveys among patients with liver disease.


  • Open Access

    Decompensated cirrhosis: an update of the BSG/BASL admission care bundle

    by Stuart McPherson, Nadir Abbas, Michael E D Allison, Dianne Backhouse, Helen Boothman, Tim Cooksley, Lynsey Corless, Thomas Crame, Timothy J S Cross, Joanna Henry, et al.

    Acute decompensated cirrhosis (DC) and acute-on-chronic liver failure are common reasons for hospital admission that have a high in-hospital mortality rate (10%–20%). Patients require a detailed assessment for precipitating factors and management of complications such as infections, ascites, acute kidney injury and hepatic encephalopathy. Multiple reports have demonstrated unwarranted variability in the care of patients with DC. In 2014, the British Society of Gastroenterology (BSG)/British Association for the Study of the Liver (BASL) DC care bundle (DCCB) was introduced to provide a structured approach for the management of patients with DC in the first 24 hours. Usage of the DCCB has been shown to improve care of patients with DC. However, despite evidence indicating the beneficial impact of the DCCB, overall usage across the UK was only 11.4% in a national audit. Our aim was to update the DCCB to incorporate recent advances in care and improve its usability and develop a strategy to improve its usage nationally. The updated bundle was developed by a multidisciplinary group of specialists from BSG, BASL and the Society for Acute Medicine with the quality of evidence supporting the bundle recommendations assessed using the Grading of Recommendation Assessment Development and Evaluation tool. Proposed minimum standards for audit were also developed. Finally, a strategy to promote usage of the bundle including education/training at a national and local level, improving accessibility for the bundle, and promotion of frameworks for use at an institutional level to improve and monitor utilisation of DCCB.


  • From O’Shaughnessy to opportunity: innovating Hepatology Trials in the UK

    by Oliver D Tavabie, Yvanne Enever, Daniel Green, Helen Crisp, Emmanouil Tsochatzis, Amir Gander, Dina Mansour, Vanessa Hebditch, Julie Adams, Adam Ashbourn, et al.

    Developing new treatments that improve outcomes for patients with decompensated cirrhosis remains an unmet area of clinical need. The UK has a rich history of being on the forefront of clinical trials for this patient group. However, there have been challenges in achieving this goal in the past decade, with several negative studies as well as trials struggling to achieve recruitment. This has been further exacerbated by the changed clinical landscape following the COVID-19 pandemic. In response to this, the O’Shaughnessy report was commissioned to identify potential opportunities to improve clinical trial performance in the UK. In this review article, we identify critical areas for the UK hepatology community to collaborate and develop sustainable partnerships for clinical trial delivery which will ensure that outcomes are representative, inclusive and patient-centred.


  • Open Access

    British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 1: compensated cirrhosis

    by Dina Mansour, Steven Masson, Debbie L Shawcross, Andrew C Douds, Emily Bonner, Lynsey Corless, Joanna A Leithead, John Hammond, Michael A Heneghan, Mussarat Nazia Rahim, et al.

    The prevalence of cirrhosis has risen significantly over recent decades and is predicted to rise further. Widespread use of non-invasive testing means cirrhosis is increasingly diagnosed at an earlier stage. Despite this, there are significant variations in outcomes in patients with cirrhosis across the UK, and patients in areas with higher levels of deprivation are more likely to die from their liver disease. This three-part best practice guidance aims to address outpatient management of cirrhosis, in order to standardise care and to reduce the risk of progression, decompensation and mortality from liver disease. Here, in part one, we focus on outpatient management of compensated cirrhosis, encompassing hepatocellular cancer surveillance, screening for varices and osteoporosis, vaccination and lifestyle measures. We also introduce a compensated cirrhosis care bundle for use in the outpatient setting. Part two concentrates on outpatient management of decompensated disease including management of ascites, encephalopathy, varices, nutrition as well as liver transplantation and palliative care. The third part of the guidance covers special circumstances encountered in managing people with cirrhosis: surgery, pregnancy, travel, managing bleeding risk for invasive procedures and portal vein thrombosis.


  • Open Access

    British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 2: decompensated cirrhosis

    by Dina Mansour, Steven Masson, Lynsey Corless, Andrew C Douds, Debbie L Shawcross, Jill Johnson, Joanna A Leithead, Michael A Heneghan, Mussarat Nazia Rahim, Dhiraj Tripathi, et al.

    There are two distinct phases in the natural history of cirrhosis: compensated disease (corresponding to Child Pugh A and early Child Pugh B disease), where the patient may be largely asymptomatic, progressing with increasing portal hypertension and liver dysfunction to decompensated disease (corresponding to Child Pugh late B-C), characterised by the development of overt clinical signs, including jaundice, hepatic encephalopathy (HE), ascites, renal dysfunction and variceal bleeding. The transition from compensated cirrhosis to decompensated cirrhosis (DC) heralds a watershed in the nature and prognosis of the disease. DC is a systemic disease, characterised by multiorgan/system dysfunction, including haemodynamic and immune dysfunction. In this second part of our three-part series on the outpatient management of cirrhosis, we address outpatient management of DC, including management of varices, ascites, HE, nutrition, liver transplantation and palliative care. We also introduce an outpatient DC care bundle. For recommendations on screening for osteoporosis, hepatocellular carcinoma surveillance and vaccination see part one of the guidance. Part 3 of the guidance focusses on special circumstances encountered in patients with cirrhosis, including surgery, pregnancy, travel, management of bleeding risk for invasive procedures and portal vein thrombosis.


  • Open Access

    Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary–secondary care interface

    by Stuart McPherson, Helen Jarvis, John McGonigle, Joan Bedlington, Jill Dean, Kate Hallsworth, Elodie Hanon, Trevor Liddle, Ahai Luvai, Dina Mansour, et al.

    Introduction Undiagnosed fatty liver disease is prevalent in the community, due to high rates of harmful alcohol consumption and/or obesity. Fatty liver disease can progress to cirrhosis and its complications. Early identification of liver disease and treatment may prevent progression to cirrhosis. Biomarkers including FIB-4, enhanced liver fibrosis (ELF), PRO-C3 and vibration controlled transient elastography (VCTE) can stage liver fibrosis, but it is not known how well they perform in a primary care population. Moreover, no assessment of long-term prognostic ability of these biomarkers has been conducted in primary care. We aim to evaluate the performance of fibrosis biomarkers in primary care to develop a pathway to detect advanced fibrosis. Methods and analysis This prospective, observational cohort study will recruit 3000 individuals with fatty liver disease risk factors (obesity, type 2 diabetes or hazardous alcohol consumption) at their primary care ‘annual chronic disease review’. Participants will have a ‘liver health check’. Two pathways will be evaluated: (1) all have FIB-4, ELF and VCTE performed, and (2) patients have an initial assessment with FIB-4 and ELF, followed by VCTE in only those with increased FIB-4 and/or ELF. Individuals with suspected significant/advanced liver fibrosis (liver stiffness measurement>8 kPa), will be reviewed in secondary care to confirm their fibrosis stage and institute treatment. The performance of FIB-4, ELF, PRO-C3, VCTE and novel biomarkers alone or in combination for advanced fibrosis/cirrhosis will be evaluated. Participants will be followed longitudinally via their electronic health records to assess long-term clinical outcomes. Ethics and dissemination Ethical approval was obtained from the London-Chelsea Research Ethics Committee (22/PR/0535; 27 June 2022). Recruitment began on 31 October 2022. Outcomes of this study will be published in peer-reviewed journals and presented at scientific meetings. A lay summary of the results will be available for study participants and will be disseminated widely by LIVErNORTH.


  • Open Access

    Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group

    by Stuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, Lynsey Corless, Quentin M Anstee, Richard J Aspinall, Stephen T Barclay, Paul N Brennan, Tessa M Cacciottolo, Robert D Goldin, et al.


  • Open Access

    Embedding assessment of liver fibrosis into routine diabetic review in primary care

    by Dina Mansour, Allison Grapes, Marc Herscovitz, Paul Cassidy, Jonathan Vernazza, Andrea Broad, Quentin M. Anstee, Stuart McPherson